Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
101.02
-1.10 (-1.08%)
Oct 6, 2025, 4:00 PM EDT - Market closed
Illumina Employees
Illumina had 10,370 employees as of December 31, 2024. The number of employees decreased by 2,020 or -16.30% compared to the previous year.
Employees
10,370
Change (1Y)
-2,020
Growth (1Y)
-16.30%
Revenue / Employee
$413,115
Profits / Employee
$121,215
Market Cap
15.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10,370 | -2,020 | -16.30% |
Dec 31, 2023 | 12,390 | -970 | -7.26% |
Dec 31, 2022 | 13,360 | 1,610 | 13.70% |
Dec 31, 2021 | 11,750 | 2,400 | 25.67% |
Dec 31, 2020 | 9,350 | 1,650 | 21.43% |
Dec 29, 2019 | 7,700 | 400 | 5.48% |
Dec 30, 2018 | 7,300 | 1,100 | 17.74% |
Dec 31, 2017 | 6,200 | 700 | 12.73% |
Dec 31, 2016 | 5,500 | 900 | 19.57% |
Dec 31, 2015 | 4,600 | 900 | 24.32% |
Dec 28, 2014 | 3,700 | 700 | 23.33% |
Dec 29, 2013 | 3,000 | 800 | 36.36% |
Dec 31, 2012 | 2,200 | -200 | -8.33% |
Dec 30, 2012 | 2,400 | 300 | 14.29% |
Dec 31, 2011 | 2,100 | 319 | 17.91% |
Dec 31, 2010 | 1,781 | 245 | 15.95% |
Dec 28, 2008 | 1,536 | 495 | 47.55% |
Dec 30, 2007 | 1,041 | 445 | 74.66% |
Dec 31, 2006 | 596 | 221 | 58.93% |
Dec 31, 2005 | 375 | 97 | 34.89% |
Dec 31, 2004 | 278 | 42 | 17.80% |
Dec 28, 2003 | 236 | 3 | 1.29% |
Dec 29, 2002 | 233 | 54 | 30.17% |
Dec 30, 2001 | 179 | 74 | 70.48% |
Dec 31, 2000 | 105 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ILMN News
- 5 days ago - Illumina launches new business to accelerate technology and data-driven discovery - PRNewsWire
- 10 days ago - ILMN Stock vs. IQV Stock - Forbes
- 13 days ago - Illumina advances personalized cancer care with new pharma development partnerships - PRNewsWire
- 18 days ago - Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - PRNewsWire
- 4 weeks ago - Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - PRNewsWire
- 5 weeks ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 2 months ago - Illumina: The Stock Is Still Undervalued - Seeking Alpha
- 2 months ago - These Analysts Boost Their Forecasts On Illumina Following Upbeat Results - Benzinga